Prothena Corporation plc的合作伙伴Bristol Myers Squibb宣布,其开发的BMS-986446 (PRX005)抗MTBR-Tau靶向抗体已获得美国食品药品监督管理局(FDA)的快速通道认定,该药物用于治疗阿尔茨海默病。
Prothena Corporation plc的合作伙伴Bristol Myers Squibb宣布,其开发的BMS-986446 (PRX005)抗MTBR-Tau靶向抗体已获得美国食品药品监督管理局(FDA)的快速通道认定,该药物用于治疗阿尔茨海默病。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.